PAR 0.00% 22.5¢ paradigm biopharmaceuticals limited..

An IL-8 Investigation, page-5

  1. 4,433 Posts.
    lightbulb Created with Sketch. 6996
    Hi Hamman,


    No is the short answer.

    Certainly another inflammatory condition that iPPS could potentially address.

    Inflammatory Bowel Disease (IBD) is the overarching condition under which diseases such as Chron's disease falls. There is definitely some real chance that iPPS can address Chron's disease which I've come across in the past thus by extrapolation, IBD being another inflammatory condition also should be a possible future indication for us.





 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
22.5¢
Change
0.000(0.00%)
Mkt cap ! $78.73M
Open High Low Value Volume
23.0¢ 23.0¢ 21.5¢ $78.13K 350.8K

Buyers (Bids)

No. Vol. Price($)
2 64880 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
22.5¢ 43479 1
View Market Depth
Last trade - 16.10pm 11/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.